Zantac (Ranitidine): The Silent Carcinogen Hidden in Medicine Cabinets

A Trusted Heartburn Drug with a Toxic Secret

For decades, Zantac (ranitidine) was one of the world's best-selling medications, trusted by millions to treat heartburn, acid reflux, and ulcers. At its peak, it was the first drug in history to reach $1 billion in global sales. But beneath this commercial success lurked a chemistry problem that would eventually pull Zantac from pharmacy shelves worldwide and trigger one of the largest pharmaceutical litigation waves in recent memory.

The NDMA Contamination Problem

In 2019, independent researchers and then the FDA discovered that ranitidine — the active ingredient in Zantac — was inherently unstable. Under certain conditions, including normal body temperature and time, it breaks down into N-nitrosodimethylamine (NDMA), a probable human carcinogen. Unlike other drug contaminations caused by manufacturing errors, this was a fundamental flaw in the molecule itself. The FDA ultimately determined that NDMA levels in ranitidine products could increase over time, particularly in warmer storage conditions.

In April 2020, the FDA requested that all manufacturers withdraw ranitidine products from the U.S. market immediately. Similar withdrawals followed in Canada, Europe, and other markets.

The Litigation Landscape

The litigation that followed was massive. Thousands of plaintiffs alleged that long-term use of Zantac had caused cancers including bladder, stomach, colon, esophageal, liver, and breast cancer. Cases were consolidated into Multi-District Litigation (MDL) in the Southern District of Florida. Major defendants included GlaxoSmithKline (original manufacturer), Sanofi, Pfizer, Boehringer Ingelheim, and numerous generic manufacturers and retailers.

In 2022, a federal judge dismissed the MDL cases, ruling that plaintiffs' expert testimony on causation was inadmissible under the Daubert standard. However, state court litigation continued, with several states proceeding with their own cases. Some defendants settled individual cases for undisclosed amounts while the broader litigation continued.

A Warning for Patients and the Industry

The Zantac case raised profound questions about drug stability and long-term safety monitoring. It exposed how a drug can be on the market for over 30 years before a fundamental safety flaw is identified — and how millions of patients may have been unknowingly exposed to carcinogens through medicine they trusted implicitly. For pharmaceutical manufacturers and regulators alike, it underscored the need for ongoing stability testing and more rigorous post-market surveillance.